PharmacyCodes



Remoxipridum [Inn-Latin] en es it fr

Remoxipridum [Inn-Latin] Brand names, Remoxipridum [Inn-Latin] Analogs

Remoxipridum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Remoxipridum [Inn-Latin] Chemical_Formula

C16H23BrN2O3

Remoxipridum [Inn-Latin] RX_link

No information avaliable

Remoxipridum [Inn-Latin] fda sheet

Remoxipridum [Inn-Latin] msds (material safety sheet)

Remoxipridum [Inn-Latin] Synthesis Reference

No information avaliable

Remoxipridum [Inn-Latin] Molecular Weight

371.269 g/mol

Remoxipridum [Inn-Latin] Melting Point

No information avaliable

Remoxipridum [Inn-Latin] H2O Solubility

74 mg/L

Remoxipridum [Inn-Latin] State

Solid

Remoxipridum [Inn-Latin] LogP

3.511

Remoxipridum [Inn-Latin] Dosage Forms

Tablet

Remoxipridum [Inn-Latin] Indication

For the treatment of schizophrenia.

Remoxipridum [Inn-Latin] Pharmacology

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.

Remoxipridum [Inn-Latin] Absorption

Rapidly absorbed. Absolute bioavailability is 90%.

Remoxipridum [Inn-Latin] side effects and Toxicity

No information avaliable

Remoxipridum [Inn-Latin] Patient Information

No information avaliable

Remoxipridum [Inn-Latin] Organisms Affected

Humans and other mammals